相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
Melanie P. Chin et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
Mohammad A. Aminzadeh et al.
XENOBIOTICA (2014)
SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
Nobuya Inagaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
Stephan A. Veltkamp et al.
CLINICAL DRUG INVESTIGATION (2013)
The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
Wenhui Zhang et al.
CLINICAL DRUG INVESTIGATION (2013)
Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
Kohei Kaku et al.
DIABETES CARE (2013)
Nrf2 activation: A potential strategy for the prevention of acute mountain sickness
Christina Lisk et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis
N. Ejskjaer et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2013)
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
Stephen Orena et al.
FRONTIERS IN PHARMACOLOGY (2013)
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes
E. Leifke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus
Stephan A. Veltkamp et al.
CLINICAL THERAPEUTICS (2012)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers
Himanshu Naik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Discovery of Piragliatin-First Glucokinase Activator Studied in Type 2 Diabetic Patients
Ramakanth Sarabu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
Charles F. Burant et al.
LANCET (2012)
Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
Jorge Rojas-Rivera et al.
INTERNATIONAL JOURNAL OF NEPHROLOGY (2012)
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
E. J. Verspohl
PHARMACOLOGICAL REVIEWS (2012)
Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases
Merouane Bencherif et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
Sherwyn L. Schwartz et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
The cost of drug development: A systematic review
Steve Morgan et al.
HEALTH POLICY (2011)
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pergola et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats
Yoshiyuki Tsujihata et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study
P. Sanwald-Ducray et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat
Sumika Ohyama et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
Riccardo C. Bonadonna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
An alpha 7 Nicotinic Acetylcholine Receptor-Selective Agonist Reduces Weight Gain and Metabolic Changes in a Mouse Model of Diabetes
Mario B. Marrero et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist
Nobuyuki Negoro et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
Agnes Benardeau et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
Robert R. Henry et al.
LANCET (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Assessing the potential of glucokinase activators in diabetes therapy
Franz M. Matschinsky
NATURE REVIEWS DRUG DISCOVERY (2009)
Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance
Aya Fujinami et al.
CLINICAL BIOCHEMISTRY (2008)
Safety issues and prospects for future generations of PPAR modulators
Anne Rubenstrunk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Brain-derived neurotrophic factor (BDNF) and type 2 diabetes
K. S. Krabbe et al.
DIABETOLOGIA (2007)
Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179
Rehan Ahmad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia
VA Pavlov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Therapeutic roles of peroxisome proliferator-activated receptor agonists
B Staels et al.
DIABETES (2005)
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Y Itoh et al.
NATURE (2003)
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
H Wang et al.
NATURE (2003)
Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in dbldb mice
S Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
分享论文
